Acute coronary syndrome (1:10), rifaximin (6:10), top medical schools for Family Medicine (8:40), proteinuria in children (10:00), antenatal steroids (13:30), and the Prevention Priorities Game (16:10).

Interview with Mark H. Greenawald, MD, Professor and Vice Chair for Academic Affairs, Department of Family and Community Medicine, Carilion Clinic and Virginia Tech Carilion School of Medicine and Course Director of the AAFP’s Chief Resident Leadership Development Program. Topics discussed include physician wellness, mentorship, listening to patient stories, and Bison Chips.

Antiepileptic drugs (1:50), dizziness (3:40), statins and dementia (8:10), jaundice in adults (9:00), practice guidelines for Botox (11:10), sertraline (12:40), and treatment of peripheral vascular disease (14:20).

Hyperlipidemia (1:30), sleep apnea (5:50), otitis media (7:10), respiratory syncytial virus (8:50), giant cell arteritis (11:00), fibroids (12:50), and "Does chocolate cause acne?" (15:20).

Heart failure treatment (1:10), patient-centered communication (5:40), membrane sweeping (10:20), opiate withdrawal (12:20), and “Primary Care Dreams” video by Jamie Katuna and Kyle Cowper (14:40).

Interview with John Meigs, MD, FAAFP, President of the American Academy of Family Physicians and family physician in Centreville, Alabama. Topics discussed include: expected changes in healthcare in 2017 and beyond, how students and family physicians can become more engaged, his favorite football team, and hidden talents.

Autism spectrum disorder (1:10), pediatric head injury (8:20), pediatric cholesterol guidelines (11:00), gastrointestinal complications in diabetes (13:20), and “Listening for a kinder, gentler, hospital experience” by Caroline Wellbery MD PhD and Eathan Janney (19:50).

Lymphadenopathy (1:10), cardiac rehab (7:10), rotator cuff injury (9:00), infant infection rule out (11:20), aripiprazole (14:10), menopause (16:30), and Holiday Myths (22:40).

Pet-related infections (2:10), PSA screening (7:00), carpal tunnel (9:20), erectile dysfunction (12:10), diabetic foot (17:00), and evolocumab (19:20).